|
Patent landscape, scope, and claims: |
United States Patent 8,772,306 (GHB-Plus-Valproate Dose-Reduction for Narcolepsy and Sleep Disorders): Scope, Claim Coverage, and Landscape
What is US 8,772,306 claiming at the broadest level?
US 8,772,306 claims methods (not composition claims) for treating sleep-related disorders using gamma-hydroxybutyrate (GHB) or a salt thereof, where the core limitation is dose reduction when valproate (or an “acid, salt, or mixture thereof”) is co-administered.
From the claim set provided, the invention is defined by three recurring pillars:
- Indication scope: excessive daytime sleepiness, cataplexy, sleep paralysis, apnea, narcolepsy, sleep time disturbances, hypnagogic hallucinations, sleep arousal, insomnia, nocturnal myoclonus (and repeatedly narcolepsy as a focused embodiment).
- Dose-reduction trigger: co-administration of valproate / divalproex sodium and an associated requirement to reduce the effective dosage amount of GHB by a threshold (at least 5%, often 15%, with ranges extending as high as 50%).
- Administration and logistics language: a treatment workflow that includes determining/confirming co-medication and then warning/recommending reducing the GHB dose, plus specific embodiments around starting concentration, pH, and optionally water dilution for a GHB salt formulation.
The claims are method claims that can be read as covering:
- Clinician-directed dosing adjustments (warning/recommending dose reductions).
- Patient instructions (recommendation to decrease).
- Practical formulation/administration parameters tied to a “GHB salt” dosing regimen (concentration and pH windows).
What is the claim-by-claim scope (and what each claim adds)?
Independent methods (functional anchors)
Claim 1 (broadest method in the set you provided) covers:
- Treating a sleep-disorder patient with GHB or salt.
- Orally administering a dose where, during concomitant administration of valproate, an acid, salt, or mixture thereof, the GHB dose is reduced by at least 5% versus a dose “normally given.”
Claims 11 and 19 shift from purely “treating” to a “safely administering” framework and then to a formulation + workflow framework.
Claim 11 covers:
- Determining if the patient “has taken, or will take” concomitant valproate / acid / salt.
- Orally administering a reduced amount of GHB at least 5% vs a dose without the concomitant administration.
Claim 19 is a more specific workflow method for narcolepsy that includes:
- Administering a therapeutically effective amount of a formulation containing a GHB salt.
- Starting at 350 to 750 mg/mL with pH 6 to 10.
- Determining valproate co-administration.
- Warning of a potential drug-drug interaction.
- Recommending reducing the GHB salt dose by at least 15%.
Key dependent claim layers (dose thresholds, dose ranges, timing, formulations)
The claim set you provided includes these limiting layers:
Dose reduction magnitude
- Claim 2: at least 15% reduction; explicitly states divalproex sodium.
- Claim 4: defines a menu of possible reduction ranges from ~5% to ~50% (multipoint ranges).
- Claim 12: at least 10% to 30%.
- Claim 13: at least 15% reduction with divalproex sodium.
- Claim 18: recommends decrease by 20% with divalproex sodium.
- Claim 28: recommends reducing by at least 20% with divalproex sodium.
- Claim 30: recommends 20% decrease in starting dose, with explicit adjusted dosing numbers.
- Claim 10 is a narrower dosage embodiment: effective dosage between 3.5 and 4 grams/day (in the generic claim 1 framework).
Baseline/target GHB dosing ranges
- Claim 3 and Claim 8: without concomitant valproate/acid adjunct, dose is 4.5 to 9 grams/day.
- Claim 7: effective dosage amount reduced from 4.5 to 9 grams/day (same conceptual baseline).
- Claim 9: effective dosage between 3 and 7 grams/day.
- Claim 10: effective dosage between 3.5 and 4 grams/day.
- Claim 30: for narcolepsy, adjusted dosage between 3.5 and 4 grams per night (oral), consistent with claim 31’s ~3.6 grams.
Timing of valproate relative to GHB
- Claim 14: valproate within two weeks of GHB administration.
- Claim 15: valproate within three days.
- Claims 20 and 21 repeat timing windows in the narcolepsy formulation workflow context (same two-week and three-day windows).
Valproate specificity
- Several claims move from “valproate, an acid, salt, or mixture thereof” to explicit divalproex sodium:
- Claim 2
- Claim 13
- Claim 18
- Claim 28
- Claim 30 (via the overall reference to divalproex sodium)
Aspirin co-administration language
- Claim 6: further comprising administering aspirin.
- Claim 17: further comprising administering aspirin.
- Claim 27: further comprising administering aspirin.
This opens potential coverage around combination treatment regimens where aspirin is given alongside GHB and/or the dose-reduction workflow.
GHB salt formulation parameters (concentration and pH)
Claim 19 adds formulation constraints:
- Starting concentration 350 to 750 mg/mL
- pH 6 to 10
Claim 22 narrows to:
- Starting concentration 450 to 550 mg/mL
Claim 24 adds:
- pH between 6.5 and 8
Claim 23 and 29 add:
- Adding water to the GHB salt formulation (optional)
Claim 32 and 34 repeat optional dilution with starting concentration and pH windows in later narcolepsy embodiments.
GHB salt compositional list
- Claim 26 limits GHB salts to “a single salt or a mixture of salts” chosen from:
- Na.GHB
- K.GHB
- Mg.(GHB)2
- Ca.(GHB)2
This is a structural limitation that can materially narrow infringement depending on the exact salt used and whether the product is in those forms.
What does this imply about literal infringement risk for different product strategies?
1) If you market a GHB product used without any dose reduction when valproate is co-administered
- Claim 1, 11, and 19 all require the concomitant administration of valproate (and/or “acid, salt, or mixture thereof”) and a reduced GHB dosage threshold.
- A regimen without the reduction would likely fall outside the claimed method steps.
2) If you include dose reduction only as a general “monitoring” or “warnings” label
- The claims repeatedly require recommending reducing the dose by a specified magnitude (at least 5%, at least 10%-30%, at least 15%, at least 20%, etc.) and often tie it to a decision step (determine/warn/recommend).
- Generic interaction warnings that do not instruct reduction by the threshold may avoid the specific claimed steps.
3) If you build the prescriber workflow around the claimed reduction thresholds
- If product instructions or clinician protocol explicitly require dose reduction by ≥5% when valproate is concomitantly administered, the risk escalates for method claims 1 and 11.
- If the protocol specifies ≥15% reduction and narcolepsy plus the GHB salt formulation parameters (starting concentration/pH) in a way that tracks claim 19, the risk moves toward the narrower embodiments.
4) If your formulation is outside the listed salts or formulation windows
- Claim 26 restricts the claimed “GHB salt” compositions to sodium/potassium/magnesium/calcium salts.
- Claim 19 and its dependents constrain concentration and pH ranges.
- If a product uses a different salt form or uses a formulation outside the concentration/pH windows, the claims containing those limitations may not read.
What is the operational “center of gravity” of the patent?
The practical center of gravity is the dose-reduction regimen conditioned on valproate co-administration:
- Minimum threshold across the broadest claims is ≥5% (claims 1 and 11).
- A common commercially meaningful tier is ≥15% and ≥20% (claims 2, 13, 18, 28, 30).
- The patent also locks in dosing mathematics through baseline and adjusted ranges (notably 4.5 to 9 g/day without valproate and ~3.5 to 4 g/night or 3.6 g/day style embodiments under valproate co-use).
How do claims handle “effective dosage amount” and baselines?
“Effective dosage amount” is not free-form. The set you provided ties it to:
- A relative reduction requirement: “at least 5% decrease” and lists many ranges in claim 4.
- Absolute ranges: “between 3 grams and 7 grams per day” and “between 3.5 grams and 4 grams per day.”
- A baseline: “without concomitant administration” is 4.5 to 9 grams per day (claims 3, 7, 8).
This creates two infringement pathways:
- Relative reduction method: show a reduction vs a no-valproate dose.
- Absolute dosage embodiment: show the reduced dosing falls within claimed gram/day windows.
How does the claim set map to a patent landscape (what you should expect around it)?
Because the claims revolve around a drug-drug interaction dosing adjustment, the landscape tends to cluster into three adjacent categories:
Category A: Interaction-driven dosing adjustments for GHB with CNS drugs
- The patent’s novelty posture is likely anchored in “valproate plus GHB” management.
- Closest competitors or follow-on patents typically cover:
- Additional co-medications (other anticonvulsants or CNS depressants).
- Different thresholds or timing language.
- Different formulations (salt forms, concentration, pH, dilution protocols).
Category B: Narcolepsy-specific GHB salt formulations and administration regimens
Claim 19 and dependent claims insert formulation constraints:
- starting concentration bands,
- pH,
- water addition/dilution,
- specific salts (Na.GHB, K.GHB, Mg.(GHB)2, Ca.(GHB)2),
- and dosing adjustments like 3.6 g.
Landscape pressure here comes from any patent focusing on:
- narcolepsy dosing regimens,
- solution/salt stability and administration,
- titration steps,
- or regulatory-ready labeling workflows.
Category C: Combination therapy regimens including aspirin
Claims 6, 17, and 27 add aspirin as a “further comprising” step. Landscape outcomes:
- if aspirin co-administration is broadly practiced in the specific marketed regimen, it can strengthen method-read-through for those dependent claims.
- if aspirin is not used, those dependent claims are less likely to be directly implicated.
Claim breadth vs. claim fragility (where validity and design-around pressure tends to concentrate)
Broadest elements
- Indication scope (multiple sleep disorders).
- Relative reduction threshold (≥5%).
- The general “determine if patient is also being administered” and then dose reduction.
Narrowing elements that can create design-around opportunities
- Explicit divalproex sodium occurrences.
- Specific GHB salt identity list.
- Starting concentration and pH windows.
- Specific timing windows (three days / two weeks).
- Absolute dose windows (3 to 7 g/day; 3.5 to 4 g/day; baseline 4.5 to 9 g/day without valproate).
For a competitor, narrowing the product to avoid one or more narrow limitations can shift risk away from dependent claims even if broad claims remain a possibility.
What are the key infringement trigger combinations embedded in the claims?
A non-exhaustive list of “must-match” combinations that operationally define risk:
| Claim anchor |
Required patient situation |
Required GHB change |
Additional gating elements |
| Claim 1 |
Patient suffering from listed sleep disorders |
Oral GHB dose reduced ≥5% during concomitant valproate/acid/salt |
At least one of: excessive daytime sleepiness, cataplexy, narcolepsy, etc. |
| Claim 2 |
Same as Claim 1 |
≥15% reduction |
Valproate = divalproex sodium |
| Claim 3 / 8 |
Same as Claim 1 |
Reduced dose while baseline (no valproate) is 4.5-9 g/day |
Baseline requirement |
| Claim 11 |
Patient receiving GHB with prospective/ongoing valproate/acid/salt |
Reduced GHB dose ≥5% |
Determining if patient “has taken, or will take” |
| Claim 19 |
Narcolepsy |
Recommend ≥15% reduction |
Starting concentration 350-750 mg/mL, pH 6-10; warn interaction |
| Claim 22 / 24 |
Narcolepsy and formulation-specific |
Recommend ≥15% reduction |
Starting concentration 450-550 mg/mL; pH 6.5-8 |
| Claim 26 |
Narcolepsy workflow |
Dose reduction via formulation |
GHB salt selected from Na.GHB/K.GHB/Mg.(GHB)2/Ca.(GHB)2 |
| Claim 30 |
Narcolepsy |
Recommend 20% decrease |
Adjusted start between 3.5-4 g per night; optionally concentration/pH tied (via claims 32-34) |
Key Takeaways
- US 8,772,306 is a method patent focused on GHB dose reduction during valproate co-administration, anchored by relative reduction thresholds starting at ≥5% and commonly escalating to ≥15% and ≥20% in dependent claims.
- The claims cover narcolepsy explicitly and also list a broader sleep-disorder indication set in the broad claims.
- The claim set combines (i) dose-reduction instructions/workflows with (ii) formulation-specific constraints in narrower embodiments (GHB salt identity list, starting concentration, and pH windows).
- For landscape assessment, the patent sits at the intersection of:
- GHB narcolepsy regimens,
- interaction-based dosing protocols involving valproate/divalproex,
- and formulation/pH/concentration handling for GHB salt solutions.
FAQs
1) Does US 8,772,306 cover changing GHB dose without valproate present?
No. The claimed methods require concomitant administration of valproate, an acid, salt, or mixture thereof as a trigger for the claimed reduction.
2) What is the minimum dose reduction explicitly required in the broadest claims you listed?
At least 5% (claims 1 and 11).
3) Are divalproex sodium and valproate treated differently in the claims?
Yes. Many dependent claims specify divalproex sodium explicitly (for example claim 2 and claim 13), tightening the trigger to that specific valproate form.
4) Do any claims tie infringement to formulation pH and concentration?
Yes. Claim 19 requires starting GHB salt formulation concentration 350-750 mg/mL and pH 6-10, with dependent claims tightening concentration (450-550 mg/mL) and pH (6.5-8).
5) Which specific GHB salts are covered in the claim set you provided?
The claims you listed cover salts selected from Na.GHB, K.GHB, Mg.(GHB)2, and Ca.(GHB)2 (claim 26).
References
[1] User-provided claim text for U.S. Patent 8,772,306 (claims 1-34).
More… ↓
⤷ Start Trial
|
